FMP
NASDAQ
92.25 USD
-0.72 (-0.78%)
Dr. Ugur Sahin M.D.
Healthcare
Biotechnology
https://www.biontech.de
NASDAQ
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122),...
0001776985
US09075V1026
09075V102
An der Goldgrube 12
49 6131 9084 0
DE
6,133
Oct 10, 2019
0001776985
NASDAQ
Biotechnology
Healthcare
09075V102
US09075V1026
DE
92.25
0.23
693.34k
21.93B
-
85.213-131.52
-86.03
-
-
-
-
22.23
-
https://www.biontech.de
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.